Proto Labs Inc. reported an insider sale and updated financial results that were both disclosed in recent regulatory filings and company announcements. On February 6, 2026, Chief Operations Officer Michael R. Kenison sold 2,500 shares of common stock at $60.00 per share, producing total proceeds of $150,000.
According to the filing, after the disposition Kenison directly holds 34,526 shares of Proto Labs. The filing also notes that the sale took place under a pre-arranged Rule 10b5-1 trading plan that was adopted on August 15, 2025. The transaction was reported to the Securities and Exchange Commission via a Form 4.
In a separate corporate disclosure, Proto Labs released its fourth-quarter 2025 financial results, which exceeded the expectations embedded in analyst forecasts for the period. The company reported earnings per share of $0.44, topping the forecasted $0.35. Revenue for the quarter was reported at $136.5 million, surpassing the anticipated $128.99 million.
The combination of an insider sale and an earnings beat was captured in market filings and company communications. The earnings announcement was followed by what the company characterized as a notable increase in investor interest. The statements and filings provide the core facts about the insider transaction and the quarterly performance, while offering limited detail on any motivations behind the trade or on the exact nature and duration of the uptick in investor attention.
All details regarding the insider sale, including the number of shares sold, sale price, ownership following the sale, the Rule 10b5-1 plan adoption date, and the Form 4 filing, are presented in the regulatory filing. Likewise, the quarterly results disclose the specific EPS and revenue figures relative to the cited analyst expectations. No additional explanations for the insider sale or for subsequent trading activity were provided in the disclosures beyond what appears in the Form 4 and the earnings release.
Contextual notes
- The insider transaction was executed under a pre-arranged trading plan adopted August 15, 2025, and was reported on a Form 4 to the SEC.
- Proto Labs posted fourth-quarter 2025 EPS of $0.44 and revenue of $136.5 million, both of which exceeded the expectations cited in the company disclosure.
- The company reported an increase in investor interest following the earnings report; no quantitative measures of that interest were provided.